Eisai Enters into Commercialization and Distribution Agreement with Gilead for JAK Inhibitor Filgotinib in Asia

TOKYO, Dec 20, 2021 – (JCN Newswire) – Eisai Co., Ltd. today announced it has entered into an agreement with Gilead Sciences, Inc. for the commercialization and distribution of filgotinib (generic name, product name: Jyseleca), an oral, JAK1 preferential inhibitor for indications of rheumatoid arthritis (RA…

Read more

This website is using cookies to improve the user-friendliness. You agree by using the website further.

Privacy policy
Skip to content